Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Get Our Latest Analysis on CRVS Corvus Pharmaceuticals Stock Up 0.3 % NASDAQ CRVS opened at $3.38 on Thursday. The stock has a market cap of $217.19 million, a price-to-earnings ratio of -3.63 and ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market uncertainties, we recommend caution. Read more to know why CRVS is a hold.

March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, I Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma ForumSOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE ...

On Thursday, 27 March 2025, Corvus Pharmaceuticals (NASDAQ: CRVS) presented at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided an update on ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations ...

On Thursday, 27 March 2025, Corvus Pharmaceuticals (NASDAQ: CRVS) presented at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided an update ...

US President Donald Trump has again singled out Ireland's pharmaceutical industry as a target for tariffs. Trump was speaking as he announced 25% tariffs on cars and car parts imported into the US.